Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 4;399(10341):2103-2112.
doi: 10.1016/S0140-6736(22)00015-0.

Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study

Collaborators, Affiliations

Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study

Susan D Reed et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2022 Sep 3;400(10354):732. doi: 10.1016/S0140-6736(22)01645-2. Lancet. 2022. PMID: 36058221 No abstract available.

Abstract

Background: Reports of perforation risk related to intrauterine devices (IUDs) inserted immediately post partum and among non-post-partum individuals are scarce, and previous studies with only 12-month follow-ups underestimate the risk. Breastfeeding at IUD insertion and insertion within 36 weeks post partum have been associated with increased risk of uterine perforation. The aim of these analyses was to compare the incidence and risks of IUD-related uterine perforations by non-post-partum and post-partum intervals at IUD insertion, and among post-partum individuals, to assess the impact of breastfeeding on these outcomes.

Methods: We did a multisite cohort study in the USA, using electronic health records (EHR). Study sites were three health-care systems and a site that used data from a health-care information exchange. The study population included individuals who were aged 50 years or younger and had an IUD insertion between Jan 1, 2001, and April 30, 2018. Individuals were excluded if they had not been in the health-care system for at least 12 months before IUD insertion. The primary outcome for this analysis was any IUD-related uterine perforation diagnosis for the first IUD insertion in this time period. Both complete and partial IUD-related perforations were identified. Chart abstraction was done to validate EHR-based algorithms or confirm perforations. The crude rate and cumulative incidence of uterine perforation were evaluated by non-post-partum and post-partum intervals at IUD insertion in the full cohort, and by breastfeeding status in a subcohort of post-partum individuals. Cox models estimated crude and adjusted hazard ratios (aHRs).

Findings: Data from 326 658 individuals in the full cohort and 94 817 individuals in the post-partum subcohort were analysed. In the full cohort, we identified 1008 uterine perforations (51·2% complete), with the 5-year cumulative incidence being the lowest in the non-post-partum group (0·29%, 95% CI 0·26-0·34). The aHR for the post-partum interval relative to non-post partum ranged from 2·73 (95% CI 1·33-5·63; 0 to 3 days post partum) to 6·71 (4·80-9·38; 4 days to ≤6 weeks post partum). The post-partum subcohort of individuals with breastfeeding information had 673 uterine perforations (62% complete), with a 5-year cumulative incidence of 1·37% (95% CI 1·24-1·52) and an increased risk with breastfeeding (aHR 1·37, 95% CI 1·12-1·66).

Interpretation: Although the risk for uterine perforation with IUD insertion 4 days to 6 weeks or less post partum is nearly seven times that of insertion non-post partum, perforation remains an incredibly rare event for all clinical time points. Despite a slight increased risk of perforation with breastfeeding at IUD insertion, the benefits of breastfeeding and effective contraception generally outweigh risks and should have little clinical impact. Therefore, IUD insertion timing should be based on individual desire for IUD contraception and patient convenience to assure an IUD insertion can occur. Careful follow-up of individuals at higher risk of uterine perforation is warranted.

Funding: Bayer AG.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests SDR received research funding from Bayer during the conduct of the study and has received royalties from UpToDate. LI received research funding from Bayer during the conduct of the study. XZ, KJR, CWS, SH, JW, and MSA are employees and MER was an employee of RTI-HS, which received research funding from Bayer during the conduct of the study. DG, MJF, JMS, FX, VYC, TMI, and HST are employees of KPSC, which received research funding from Bayer during conduct of the study. JLG is an employee of RI, which received research funding from Bayer during the conduct of the study. JFP has received research funding from CooperSurgical, Bayer Healthcare Pharmaceutical, and Merck & Co. MAA, MM, ALA, and GC are employees of and TR-B and DAP were employees of KPNC, which received research funding from Bayer during the conduct of the study. AA, FP, and JS are employees of Bayer, the marketing authorisation holder for three IUD brands, among others, that were included in this study.

Comment in

Similar articles

Cited by

LinkOut - more resources